Inovio wins new Overweight at Piper Sandler on potential FDA nod for lead drug Inovio wins new Overweight at Piper Sandler on potential FDA nod for lead drug Post ContentinoRead More You might also be interested in reading WeRide Non-GAAP EPADS of -$0.18, revenue of $17.8M. July 9, 2025 In Mainstream ← Previous post Next post →